Share：
Share this content in WeChat
X
[Chinese][PDF]105287
• Review •
Distribution and deposition of magnetic resonance gadolinium contrast agents in body: current status
LIU Zhe  CHENG Yan-nan  YANG Jian 

DOI:10.12015/issn.1674-8034.2017.09.014.


[Abstract] Contrast-enhanced Magnetic resonance imaging (CE-MRI) is widely used in diagnosis and differential diagnosis diseases due to the high relaxation rate of gadolinium contrast agent. In the United States, more than 10 million patients accounting for 40%—50% of all MRI examinations undergoing CE-MRI which is considered as a safety method. But many literatures have reported that gadolinium contrast agent administration have been associated with nephrogenic systemic fibrosis (NSF) in whom with severely compromised renal function, some found that gadolinium could deposite in the skin, some organs and bone tissues. Recently, more studies have shown obviously evidence that gadolinium may deposit in some specific brain structures who with nomal renal function, such as globus pallidus and dentate nucleus. After repeated CE-MRI examinations we could find higher signal intensity in the dentate nucleus and globus pallidus on unenhanced T1-weighted MR images. However, its mechanism and clinical significances remain to be unclear. Therefore, this paper will review the literatures on the application of magnetic resonance gadolinium contrast agent, summarizing the classifications and risk levels, biodistribution and deposition, possible mechanism and clinical significance, providing a powerful reference in selection of gadolinium contrast in clinic.
[Keywords] Gadolinium DTPA；Magnetic resonance imaging；Tissue distribution

LIU Zhe Department of Diagnostic Radiology, the First Affiliated Hospital of Xi’an Jiaotong University, Xi'an 710061, China

CHENG Yan-nan Department of Diagnostic Radiology, the First Affiliated Hospital of Xi’an Jiaotong University, Xi'an 710061, China

YANG Jian* Department of Diagnostic Radiology, the First Affiliated Hospital of Xi’an Jiaotong University, Xi'an 710061, China

*Correspondence to: Yang J, Email: cjr.yangjian@vip.163.com

Conflicts of interest   None.

ACKNOWLEDGMENTS  This study was supported by the National Key Research and Development Program of China No. 2016YFC0100300 National Natural Science Foundation of China No. 81471631, 81171317 The 2011 New Century Excellent Talent Support Plan of the Ministry of Education, China No. NCET-11-0438 The Clinical Research Award of the First Affiliated Hospital of Xi’an Jiaotong University No. XJTU1AF-CRF-2015-004
Received  2017-04-21
Accepted  2017-07-28
DOI: 10.12015/issn.1674-8034.2017.09.014
DOI:10.12015/issn.1674-8034.2017.09.014.

[1]
Zhou Z, Lu ZR. Gadolinium-based contrast agents for magnetic resonance cancer imaging. Wires Nanomed Nanobi, 2013, 5(1): 1-18.
[2]
Grobner T. Gadolinium-a specific trigger for the development of nephrogenic fibrosing dermopathy and nephrogenic systemic fibrosis? Nephrol Dial Transpl, 2006, 21(4): 1104-1108.
[3]
Marckmann P, Skov L, Rossen K, et al. Nephrogenic systemic fibrosis: suspected causative role of gadodiamide used for contrast-enhanced magnetic resonance imaging. J Am Soc Nephrol, 2006,17(9): 2359-2362.
[4]
Ramalho J, Semelka RC, Ramalho M, et al. Gadolinium-based contrast agent accumulation and toxicity: an update. Am J Neuroradiol, 2016, 37(7): 1192-1198.
[5]
Frenzel T, Lengsfeld P, Schirmer H, et al. Stability of gadolinium-based magnetic resonance imaging contrast agents in human serum at 37 C. Invest Radiol, 2008, 43(12): 817-828.
[6]
Weberling LD, Kieslich PJ, Kickingereder P, et al. Increased signal intensity in the dentate nucleus on unenhanced T1-weighted images after gadobenate dimeglumine administration. Invest Radiol, 2015, 50(11): 743-748.
[7]
Bhargava R, Hahn G, Hirsch W, et al. Contrast-enhanced magnetic resonance imaging in pediatric patients: review and recommendations for current practice. Magn Reson Insights, 2013, 20(6): 95-111.
[8]
Thomsen HS, Morcos SK, Almén T, et al. Nephrogenic systemic fibrosis and gadolinium-based contrast media: updated ESUR Contrast Medium Safety Committee guidelines. Eur Radiol, 2013,23(2): 307-318.
[9]
Aime S, Caravan P. Biodistribution of gadolinium-based contrast agents, including gadolinium deposition. J Magn Reson Imaging, 2009, 30(6): 1259-1267.
[10]
Lin SP, Brown JJ. MR contrast agents: physical and pharmacologic basics. J Magn Reson Imaging, 2007, 25(5): 884-899.
[11]
Sadowski EA, Bennett LK, Chan MR, et al. Nephrogenic systemic fibrosis: risk factors and incidence estimation. Radiology, 2007,243(1): 148-157.
[12]
Mendichovszky IA, Marks SD, Simcock CM, et al. Gadolinium and nephrogenic systemic fibrosis: time to tighten practice. Pediatr Radiol, 2008, 38(5): 489-496.
[13]
Gibson SE, Farver CF, Prayson RA. Multiorgan involvement in nephrogenic fibrosing dermopathy: an autopsy case and review of the literature. Arch Pathol Lab Med, 2006, 130(2): 209-212.
[14]
Kay J, Bazari H, Avery LL, et al. Case 6-2008: a 46-year-old woman with renal failure and stiffness of the joints and skin. New Engl J Med, 2008, 358(8): 827-838.
[15]
Swaminathan S, High WA, Ranville J, et al. Cardiac and vascular metal deposition with high mortality in nephrogenic systemic fibrosis. Kidney Int, 2008, 73(12): 1413-1418.
[16]
Singh M, Davenport A, Clatworthy I, et al. A follow-up of four cases of nephrogenic systemic fibrosis: is gadolinium the specific trigger? Brit J Dermatol, 2008, 158(6): 1358-1362.
[17]
Wiginton CD, Kelly B, Oto A, et al. Gadolinium-based contrast exposure, nephrogenic systemic fibrosis, and gadolinium detection in tissue. Am J Roentgenol, 2008, 190(4): 1060-1068.
[18]
Abraham JL, Thakral C, Skov L, et al. Dermal inorganic gadolinium concentrations: evidence for in vivo transmetallation and long-term persistence in nephrogenic systemic fibrosis. Brit J Dermatol, 2008,158(2): 273-280.
[19]
Gibby WA, Gibby KA, Gibby WA. Comparison of Gd DTPA-BMA (Omniscan) versus Gd HP-DO3A (ProHance) retention in human bone tissue by inductively coupled plasma atomic emission spectroscopy. Invest Radiol, 2004, 39(3): 138-142.
[20]
White GW, Gibby WA, Tweedle MF. Comparison of Gd (DTPA-BMA) (Omniscan) versus Gd (HP-DO3A) (ProHance) relative to gadolinium retention in human bone tissue by inductively coupled plasma mass spectroscopy. Invest Radiol, 2006, 41(3): 272-278.
[21]
Darrah TH, Prutsman-Pfeiffer JJ, Poreda RJ, et al. Incorporation of excess gadolinium into human bone from medical contrast agents. Metallomics, 2009, 1(6): 479-488.
[22]
Kanda T, Ishii K, Kawaguchi H, et al. High signal intensity in the dentate nucleus and globus pallidus on unenhanced T1-weighted MR images: relationship with increasing cumulative dose of a gadolinium-based contrast material. Radiology, 2013, 270(3): 834-841.
[23]
Bird ED, Anton AH, Bullock B. The effect of manganese inhalation on basal ganglia dopamine concentrations in rhesus monkey. Neurotoxicology, 1983, 5(1): 59-65.
[24]
Newland MC, Ceckler TL, Kordower JH, et al. Visualizing manganese in the primate basal ganglia with magnetic resonance imaging. Exp Neurol, 1989, 106(3): 251-258.
[25]
Mirowitz SA, Westrich TJ, Hirsch JD. Hyperintense basal ganglia on T1-weighted MR images in patients receiving parenteral nutrition. Radiology, 1991, 181(1): 117-120.
[26]
Shin YC, Kim E, Cheong HK, et al. High signal intensity on magnetic resonance imaging as a predictor of neurobehavioral performance of workers exposed to manganese. Neurotoxicology, 2007, 28(2): 257-262.
[27]
Zhang Y, Cao Y, Shih GL, et al. Extent of signal hyperintensity on unenhanced T1-weighted brain MR images after more than 35 administrations of linear gadolinium-based contrast agents. Radiology, 2017, 282(2): 516-525.
[28]
Errante Y, Cirimele V, Mallio CA, et al. Progressive increase of T1 signal intensity of the dentate nucleus on unenhanced magnetic resonance images is associated with cumulative doses of intravenously administered gadodiamide in patients with normal renal function, suggesting dechelation. Invest Radiol, 2014, 49(10): 685-690.
[29]
McDonald RJ, McDonald JS, Kallmes DF, et al. Intracranial gadolinium deposition after contrast-enhanced MR imaging. Radiology, 2015, 275(3): 772-782.
[30]
Quattrocchi CC, Mallio CA, Errante Y, et al. Gadodiamide and dentate nucleus T1 hyperintensity in patients with meningioma evaluated by multiple follow-up contrast-enhanced magnetic resonance examinations with no systemic interval therapy. Invest Radiol, 2015, 50(7): 470-472.
[31]
Kanda T, Osawa M, Oba H, et al. High signal intensity in dentate nucleus on unenhanced T1-weighted MR images: association with linear versus macrocyclic gadolinium chelate administration. Radiology, 2015, 275(3): 803-809.
[32]
Ramalho J, Castillo M, AlObaidy M, et al. High signal intensity in globus pallidus and dentate nucleus on unenhanced T1-weighted MR images: evaluation of two linear gadolinium-based contrast agents. Radiology, 2015, 276(3): 836-844.
[33]
Kanda T, Matsuda M, Oba H, et al. High T1 signal intensity in dentate nucleus after multiple injections of linear gadolinium chelates response. Radiology, 2015, 276(2): 617-617.
[34]
Weberling LD, Kieslich PJ, Kickingereder P, et al. Increased signal intensity in the dentate nucleus on unenhanced T1-weighted images after gadobenate dimeglumine administration. Invest Radiol, 2015,50(11): 743-748.
[35]
Stojanov DA, Aracki-Trenkic A, Vojinovic S, et al. Increasing signal intensity within the dentate nucleus and globus pallidus on unenhanced T1W magnetic resonance images in patients with relapsing-remitting multiple sclerosis: correlation with cumulative dose of a macrocyclic gadolinium-based contrast agent, gadobutrol. Eur Radiol, 2016, 26(3): 807-815.
[36]
Kanda T, Fukusato T, Matsuda M, et al. Gadolinium-based contrast agent accumulates in the brain even in subjects without severe renal dysfunction: evaluation of autopsy brain specimens with inductively coupled plasma mass spectroscopy. Radiology, 2015, 276(1): 228-232.
[37]
Zobel BB, Quattrocchi CC, Errante Y, et al. Gadolinium-based contrast agents: did we miss something in the last 25 years? Radiol Med, 2016, 121(6): 478-481.
[38]
朱飞鹏，张龙江，卢光明.肾源性系统性纤维化与磁共振含钆对比剂.放射学实践, 2010, 25(2): 219-221.
[39]
Prybylski JP, Maxwell E, Sanchez CC, et al. Gadolinium deposition in the brain: lessons learned from other metals known to cross the blood-brain barrier. Magn Reson Imaging, 2016, 34(10): 1366-1372.
[40]
Sanyal S, Marckmann P, Scherer S, et al. Multiorgan gadolinium (Gd) deposition and fibrosis in a patient with nephrogenic systemic fibrosis-an autopsy-based review. Nephrol Dial Transpl, 2011,26(11): 3616-3626.
[41]
Hao D, Ai T, Goerner F, et al. MRI contrast agents: basic chemistry and safety. J Magn Reson Imaging, 2012, 36(5): 1060-1071.

PREV Pathophysiology and imaging diagnosis of main pulmonary artery dilatation in patients with chronic mountain sickness
NEXT MRI evaluation of pituitary macroadenomas tumor consistency
  


LINK


Tel & Fax: +8610-67113815    E-mail: editor@cjmri.cn